
Jonathan Vernon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2429264/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immunomodulatory streptococci that inhibit CXCL8 secretion and NFήB activation are common members of the oral microbiota. Journal of Medical Microbiology, 2021, 70, .	1.8	8
2	Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 169-177.	2.9	50
3	Antimicrobial Dye-Conjugated Polyglobalide-Based Organogels. ACS Applied Polymer Materials, 2020, 2, 2927-2933.	4.4	8
4	Burden of <i>Clostridium difficile</i> Infection (CDI) Across Whole Healthcare Economies and European Borders; COMBACTE-CDI Results. Infection Control and Hospital Epidemiology, 2020, 41, s24-s25.	1.8	1
5	Effect of fluoroquinolone resistance mutation Thr-82→lle on Clostridioides difficile fitness. Journal of Antimicrobial Chemotherapy, 2019, 74, 877-884.	3.0	11
6	Investigating the transient and persistent effects of heat on Clostridium difficile spores. Journal of Medical Microbiology, 2019, 68, 1445-1454.	1.8	4
7	Investigating the effect of supplementation on Clostridioides (Clostridium) difficile spore recovery in two solid agars. Anaerobe, 2018, 50, 38-43.	2.1	2
8	Understanding Clostridium difficile Colonization. Clinical Microbiology Reviews, 2018, 31, .	13.6	206
9	The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011–2014. Clinical Microbiology and Infection, 2018, 24, 724-731.	6.0	96
10	<i>In Vitro</i> Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	10
11	Efficacy of vancomycin extended-dosing regimens for treatment of simulated <i>Clostridium difficile</i> infection within an <i>in vitro</i> human gut model. Journal of Antimicrobial Chemotherapy, 2016, 71, 986-991.	3.0	14
12	Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators. Antimicrobial Agents and Chemotherapy, 2016, 60, 689-692.	3.2	25
13	<i>In vitro</i> susceptibility of <i>Clostridium difficile</i> to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against <i>C. difficile</i> . Journal of Antimicrobial Chemotherapy, 2015, 70, 1751-1756.	3.0	32
14	Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clinical Microbiology and Infection, 2015, 21, 248.e9-248.e16.	6.0	218